Pharmacologic treatment of thalassemia intermedia with hydroxyurea-Reference-Cited by-同舟云学术

Pharmacologic treatment of thalassemia intermedia with hydroxyurea

Published:1994-09 Issue:3 Volume:125 Page:490-492
ISSN:0022-3476
Container-title:The Journal of Pediatrics
language:en
Short-container-title:The Journal of Pediatrics

Author:

Hajjar Fouad M.,Pearson Howard A.

Publisher

Elsevier BV

Subject

Pediatrics, Perinatology, and Child Health

Reference9 articles.

1. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies;Stamatoyannopoulos;Annu Rev Med,1992

2. Pharmacologic manipulation of fetal hemoglobin: update on clinical trials with hydroxyurea;Dover;Ann NY Acad Sci,1990

3. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta-plus thalassemia;Ley;N Engl J Med,1982

4. 5-Azacytidine treatment in a beta-thalassemic patient unable to be transfused due to multiple alloantibodies;Dunbar;Br J Haematol,1989

5. Pharmacological manipulation of globin gene expression with 5-azacytidine has produced long-term therapeutic benefits in two patients with beta-thalassemia;Lowrey;Blood,1991

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients;Indian Journal of Hematology and Blood Transfusion;2023-01-03

2. Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role;ASSAY and Drug Development Technologies;2022-01-01

3. Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia;Indian Pediatrics;2021-07

4. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia;Annals of Hematology;2018-06-21

5. Thalassemia Syndromes;Hematology;2018